Molecular imaging of inflammation holds promise as a noninvasive biomarker for diagnosing disease, establishing prognosis, and gauging response to therapies.
Answers are grounded in this paper and cite their sources.
May support noninvasive biomarker assessment of inflammation; leaves open prospective validation before clinical adoption.
The ability to image inflammation in vivo can improve our understanding of the pathophysiology underlying various disease etiologies, including cancer, atherosclerosis, and neurodegeneration. A great wealth of preclinical and translational research has been and is currently being developed to decipher the involvement of the immune system in disease pathophysiology, quantify the course of a disease, and visualize the potential detrimental effects of excessive inflammation. Down the road, the ultimate goal is to have clinical noninvasive in vivo imaging biomarkers of inflammation that will help diagnose disease, establish prognosis, and gauge response to preventative and therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Dima A. Hammoud (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: